Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes.
Ann Hematol
; 103(2): 437-442, 2024 Feb.
Article
in En
| MEDLINE
| ID: mdl-38060001
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Polycythemia Vera
Limits:
Humans
Language:
En
Journal:
Ann Hematol
Journal subject:
HEMATOLOGIA
Year:
2024
Document type:
Article
Affiliation country:
Italy
Country of publication:
Germany